MCID: KRT006
MIFTS: 55

Keratoconjunctivitis

Categories: Infectious diseases, Eye diseases

Aliases & Classifications for Keratoconjunctivitis

Summaries for Keratoconjunctivitis

MalaCards based summary : Keratoconjunctivitis is related to vernal keratoconjunctivitis and atopic keratoconjunctivitis. An important gene associated with Keratoconjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Zinc and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and thyroid, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 76 Keratoconjunctivitis is inflammation (\"-itis\") of the cornea and... more...

Related Diseases for Keratoconjunctivitis

Diseases related to Keratoconjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 376)
# Related Disease Score Top Affiliating Genes
1 vernal keratoconjunctivitis 33.4 CCL11 ICAM1 IL13 IL4 IL5 RNASE3
2 atopic keratoconjunctivitis 32.9 IFNG IL2 IL3 IL4 IL5 RNASE3
3 keratoconjunctivitis sicca 32.6 CD79A IL4 NGF TLR9 TNF
4 graft-versus-host disease 30.6 IFNG IL2 TNF
5 cellulitis 30.3 IL5 RNASE3 TNF
6 papillary conjunctivitis 30.2 CCL11 CXCL8 IL4
7 uveitis 30.2 ICAM1 IFNG IL4 TNF
8 giant papillary conjunctivitis 29.8 CCL11 CXCL8 IL4 RNASE3
9 alopecia areata 29.7 ICAM1 IFNG IL2 TNF
10 esophagitis 29.5 CCL11 CXCL8 IL13 IL5
11 human immunodeficiency virus type 1 29.4 CCL11 IFNG IL2 TNF
12 sleep apnea 29.4 CXCL8 ICAM1 TNF
13 peritonitis 29.4 CXCL8 ICAM1 TNF
14 chlamydia 29.3 CD79A CXCL8 IFNG TNF
15 lichen planus 29.3 ICAM1 IFNG IL4 TLR9 TNF
16 ocular cicatricial pemphigoid 29.2 CD79A IL4 NGF RNASE3
17 pleurisy 28.6 CXCL8 ICAM1 IFNG IL2 TNF
18 otitis media 28.4 CCL11 CD79A CXCL8 RNASE3 TNF
19 common variable immunodeficiency 28.3 CD79A IFNG IL2 IL4 TLR9 TNF
20 colitis 28.2 CXCL8 IFNG IL2 IL4 TLR9 TNF
21 dermatitis 28.2 CCL11 CCL17 IFNG IL13 IL4 IL5
22 pneumonia 28.2 CCL11 CXCL8 IL13 IL5 TLR9 TNF
23 allergic conjunctivitis 28.2 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
24 rheumatoid arthritis 28.0 CD79A CXCL8 ICAM1 IFNG IL2 IL4
25 conjunctivitis 28.0 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
26 autoimmune disease 27.9 CD79A IFNG IL2 IL4 IL5 TLR9
27 erythema multiforme 27.5 CCL17 CD79A ICAM1 IFNG IL2 TNF
28 allergic rhinitis 26.5 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
29 allergic asthma 26.5 CCL11 CCL17 CXCL8 IFNG IL13 IL4
30 rhinitis 26.3 CCL11 CXCL8 ICAM1 IL13 IL4 IL5
31 dermatitis, atopic 23.7 CCL11 CCL17 CXCL8 ICAM1 IFNG IL13
32 asthma 22.5 CCL11 CCL17 CD79A CXCL8 ICAM1 IFNG
33 superior limbic keratoconjunctivitis 12.4
34 punctate epithelial keratoconjunctivitis 12.0
35 neurotrophic keratoconjunctivitis 11.9
36 sjogren syndrome 11.8
37 phlyctenulosis 11.7
38 shipyard eye 11.7
39 exposure keratitis 11.0
40 mycoplasmal pneumonia 10.9 IFNG IL4
41 loeffler endocarditis 10.9 IL5 RNASE3
42 eosinophilic fasciitis 10.9 IFNG IL5
43 virus associated hemophagocytic syndrome 10.9 IL2 IL4
44 pemphigoid gestationis 10.9 CCL11 IL5
45 cytokine deficiency 10.9 IL13 IL5
46 myelopathy, htlv-1-associated 10.9
47 aplasia of lacrimal and salivary glands 10.9
48 dry eye syndrome 10.9
49 tropical spastic paraparesis 10.9
50 retrovirus-associated myelopathy 10.9

Comorbidity relations with Keratoconjunctivitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Keratoconjunctivitis:



Diseases related to Keratoconjunctivitis

Symptoms & Phenotypes for Keratoconjunctivitis

MGI Mouse Phenotypes related to Keratoconjunctivitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 IL4 ICAM1 IFNG IL5 IL13 AOC1
2 homeostasis/metabolism MP:0005376 10.11 CD79A ICAM1 IL4 IL5 IFNG NGF
3 immune system MP:0005387 10.06 IL4 ICAM1 IFNG IL5 IL13 CCL11
4 digestive/alimentary MP:0005381 10.03 IL4 ICAM1 IFNG IL5 IL13 IL2
5 neoplasm MP:0002006 9.73 IL2 CD79A ICAM1 IL5 IFNG TNF
6 no phenotypic analysis MP:0003012 9.7 IL4 IFNG NGF IL13 IL2 CD79A
7 respiratory system MP:0005388 9.5 IL4 IL5 IFNG IL13 CCL11 IL2
8 vision/eye MP:0005391 9.17 IL2 ICAM1 IL4 IFNG AOC1 NGF

Drugs & Therapeutics for Keratoconjunctivitis

Drugs for Keratoconjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 245)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 23994
2
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 9004-61-9 53477741
3
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 56-81-5 753
4
Loteprednol Approved Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 444025 9865442
5
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 299-42-3 9294
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-82-4 7028
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
8
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
9
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 445643 439492
10
Povidone Approved Phase 4,Not Applicable 9003-39-8
11
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
12
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
13
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
14
Ganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 82410-32-0 3454
15
Azithromycin Approved Phase 4 83905-01-5 55185 447043
16
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
17
Ofloxacin Approved Phase 4 82419-36-1 4583
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
19
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
20
Histamine Approved, Investigational Phase 4,Phase 3 75614-87-8, 51-45-6 774
21
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
22
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
23
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
24
Dipivefrin Approved Phase 4 52365-63-6 3105
25
Povidone-iodine Approved Phase 4 25655-41-8
26
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
27
Sorbitol Approved Phase 4 50-70-4 5780
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
29
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
30
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Not Applicable 1406-66-2 14986
31
Vitamin D3 Approved, Nutraceutical Phase 4,Not Applicable 67-97-0 6221 5280795
32
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-02-9 14985
33
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Not Applicable 8001-79-4
34
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
35
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
36
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2 91714-94-2 60726
37 cadexomer iodine Phase 4,Not Applicable
38 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Retinol palmitate Phase 4
40 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Not Applicable
41 Micronutrients Phase 4,Not Applicable
42 Nasal Decongestants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Tocopherols Phase 4,Not Applicable
46 Tocotrienols Phase 4,Not Applicable
47 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
48 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Trace Elements Phase 4,Not Applicable
50 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 494)
# Name Status NCT ID Phase Drugs
1 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
2 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
3 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
4 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
5 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
6 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
7 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
8 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
9 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
10 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
11 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
12 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
13 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
14 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
15 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
16 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
17 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
18 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
19 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
20 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
21 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
22 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
23 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
24 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops Completed NCT02758327 Phase 4 TheraTears Lubricating Eye Drops
25 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® Completed NCT02554981 Phase 4 Cyclosporine 0.05% Ophthalmic Emulsion
26 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
27 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4 azithromycin ophthalmic solution, 1%;Visine® for Contacts®
28 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
29 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
30 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
31 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4 cyclosporine 0.05% ophthalmic emulsion;carboxymethylcellulose-based lubricant eye drops
32 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
33 Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Completed NCT01970917 Phase 4
34 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
35 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
36 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
37 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
38 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
39 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
40 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
41 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4 Optive
42 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
43 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
44 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
45 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
46 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
47 Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Completed NCT01198782 Phase 4
48 Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery Completed NCT00909324 Phase 4 Pre-LASIK 0.3% hypromellose;Post-LASIK 0.3% hypromellose
49 Systane Clinical Experience Study Completed NCT00818909 Phase 4
50 Efficacy and Acceptability of Two Lubricant Eye Drops Completed NCT00756678 Phase 4 Lubricant Eye Drops (Optive™);Lubricating Eye Drops (blink® Tears)

Search NIH Clinical Center for Keratoconjunctivitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: keratoconjunctivitis

Genetic Tests for Keratoconjunctivitis

Anatomical Context for Keratoconjunctivitis

MalaCards organs/tissues related to Keratoconjunctivitis:

41
Eye, Testes, Thyroid, T Cells, Salivary Gland, Bone, Neutrophil

Publications for Keratoconjunctivitis

Articles related to Keratoconjunctivitis:

(show top 50) (show all 1143)
# Title Authors Year
1
Atopic keratoconjunctivitis: A diagnostic dilemma-a case report. ( 29668589 )
2018
2
Infectious keratoconjunctivitis in semi-domesticated Eurasian tundra reindeer (Rangifer tarandus tarandus): microbiological study of clinically affected and unaffected animals with special reference to cervid herpesvirus 2. ( 29338721 )
2018
3
Assessment of corneal and conjunctival metaplasia by impression cytology during the treatment of canine keratoconjunctivitis sicca. ( 29958527 )
2018
4
Recalcitrant Atopic Keratoconjunctivitis in Children: A Case Report and Literature Review. ( 29610174 )
2018
5
High Inflammatory Infiltrate Correlates With Poor Symptomatic Improvement After Surgical Treatment for Superior Limbic Keratoconjunctivitis. ( 29346129 )
2018
6
Adenovirus-related epidemic keratoconjunctivitis outbreak at a hospital-affiliated ophthalmology clinic. ( 29305276 )
2018
7
Corneal staining patterns in vernal keratoconjunctivitis: the new VKC-CLEK scoring scale. ( 29367201 )
2018
8
Epidemic Keratoconjunctivitis: (Superficial Punctate Keratitis, Keratitis Subepithelialis, Keratitis Maculosa, Keratitis Nummularis) With a Review of the Literature and a Report of 125A Cases. ( 29793576 )
2018
9
Immunohistochemical evaluation of lymphocyte populations in the nictitans glands of normal dogs and dogs with keratoconjunctivitis sicca. ( 29445621 )
2018
10
Efficacy of HL036 versus Cyclosporine A in the Treatment of Naturally Occurring Canine Keratoconjunctivitis Sicca. ( 29634381 )
2018
11
Epidemic keratoconjunctivitis cases resulting from adenovirus type 8 and 54 detected at Fukuoka University Hospital between 2014 and 2015. ( 29709978 )
2018
12
Increased Lacrimal Fluid Level of HMGB1 in Vernal Keratoconjunctivitis. ( 29847189 )
2018
13
Autonomic reinnervation and functional regeneration in autologous transplanted submandibular glands in patients with severe keratoconjunctivitis sicca. ( 29695713 )
2018
14
Anterior segment optical coherence tomography of microsporidial keratoconjunctivitis. ( 29676317 )
2018
15
Determinants of Outcomes of Adenoviral Keratoconjunctivitis. ( 29602567 )
2018
16
Re: Topical Tacrolimus for Corneal Subepithelial Infiltrates Secondary to Adenoviral Keratoconjunctivitis. ( 29664748 )
2018
17
Topical Tacrolimus 0.03% for Maintenance Therapy in Steroid-Dependent, Recurrent Phlyctenular Keratoconjunctivitis. ( 29309358 )
2018
18
Clinical Severity Classification using Automated Conjunctival Hyperemia Analysis Software in Patients with Superior Limbic Keratoconjunctivitis. ( 29336627 )
2018
19
Vernal keratoconjunctivitis in human immunodeficiency virus - The possible role of T-helper 1-T-helper 2 shift. ( 29941754 )
2018
20
Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast. ( 29958030 )
2018
21
SjAPgren-Like Lacrimal Keratoconjunctivitis in Germ-Free Mice. ( 29438346 )
2018
22
Vernal keratoconjunctivitis. ( 29391772 )
2018
23
Outcomes and Rationale of Excision and Mucous Membrane Grafting in Palpebral Vernal Keratoconjunctivitis. ( 29040121 )
2018
24
Recombinant type Human mastadenovirus D85 associated with epidemic keratoconjunctivitis since 2015 in Japan. ( 29396992 )
2018
25
Nuclear parameters and chromatin remodeling in epithelial cells and lymphocytes from the palpebral conjunctiva of dogs with keratoconjunctivitis sicca. ( 29493861 )
2018
26
Investigation of the efficacy of alcohol-based solutions on adenovirus serotypes 8, 19 and 37, the common cause of epidemic keratoconjunctivitis, after an adenovirus outbreak occurred in the hospital. ( 29792970 )
2018
27
Molecular typing and whole genome next generation sequencing of human adenovirus 8 strains recovered from four 2012 outbreaks of keratoconjunctivitis in New York State. ( 29750363 )
2018
28
Optimising tear replacement rheology in canine keratoconjunctivitis sicca. ( 29303147 )
2018
29
Clinical trials with multiple endpoints can establish a correlation, but not (yet) causality, between dietary supplementation with omega-3 fatty acids and keratoconjunctivitis sicca. ( 29781353 )
2018
30
Clinical and virological analysis of epidemic keratoconjunctivitis caused by adenovirus type 54 in a regional ophthalmic clinic in Kyushu, Japan. ( 29593376 )
2018
31
Microvascular Submandibular Gland Transplantation for Severe Keratoconjunctivitis Sicca: A Single-Institution Experience of 56 Cases. ( 29864431 )
2018
32
Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study. ( 29040120 )
2018
33
Quality of life and clinical characterization of patients with vernal keratoconjunctivitis in a pediatric population in Colombia. ( 29338965 )
2018
34
Comparative study of 0.1% hyaluronic acid versus 0.5% carboxymethylcellulose in patients with dry eye associated with moderate keratitis or keratoconjunctivitis. ( 29928109 )
2018
35
Simple methods to optimize the success in microsurgical submandibular gland transplantation for the treatment of patients with keratoconjunctivitis. ( 29451330 )
2018
36
Rheumatoid factor isotype and Ro epitope distribution in primary SjAPgren syndrome and rheumatoid arthritis with keratoconjunctivitis sicca. ( 29936570 )
2018
37
Use of clinical vignette questionnaires to investigate the variation in management of keratoconjunctivitis sicca and acute glaucoma in dogs. ( 29275324 )
2018
38
Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial. ( 28832739 )
2017
39
Canine oral mucosa evaluation as a potential autograft tissue for the treatment of unresponsive keratoconjunctivitis sicca. ( 28470741 )
2017
40
Notes from the Field: Epidemic Keratoconjunctivitis Outbreak Associated with Human Adenovirus Type 8 - U.S. Virgin Islands, June-November 2016. ( 28771460 )
2017
41
Supratarsal injection of triamcinolone for severe vernal keratoconjunctivitis in children. ( 28832741 )
2017
42
A Case of Type 54 Human Mastadenovirus Keratoconjunctivitis Causing Severe Broad Epithelial Defect Ten Years after LASIK Surgery. ( 28674318 )
2017
43
Polyparaneoplastic Manifestations of Malignant Thymoma: A Unique Case of Myasthenia, Autoimmune Hepatitis, Pure Red Cell Aplasia, and Keratoconjunctivitis Sicca. ( 28744421 )
2017
44
Long-term use of 0.003% tacrolimus suspension for treatment of vernal keratoconjunctivitis. ( 29118487 )
2017
45
Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study. ( 28399035 )
2017
46
Invasive <em>Neisseria gonorrhoeae</em> producing pre-septal cellulitis and keratoconjunctivitis: diagnosis and management. ( 28899333 )
2017
47
Acute keratoconjunctivitis due to contamination of contact lens care solution with histamine-producing Raoultella species: A case report. ( 29390396 )
2017
48
Ocular Surface Squamous Neoplasia Associated with Atopic Keratoconjunctivitis. ( 28275599 )
2017
49
Expression of IL-33 in ocular surface epithelium induces atopic keratoconjunctivitis with activation of group 2 innate lymphoid cells in mice. ( 28855579 )
2017
50
Kingella kingae Keratitis in a Child with Underlying Vernal Keratoconjunctivitis. ( 28546880 )
2017

Variations for Keratoconjunctivitis

Expression for Keratoconjunctivitis

Search GEO for disease gene expression data for Keratoconjunctivitis.

Pathways for Keratoconjunctivitis

Pathways related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 AOC1 CCL11 CD79A CXCL8 ICAM1 IFNG
2
Show member pathways
13.86 CCL11 CCL17 CXCL8 IL13 IL2 IL3
3
Show member pathways
13.72 CCL11 CCL17 CXCL8 IFNG IL13 IL2
4
Show member pathways
13.53 CCL11 CCL17 CXCL8 IFNG IL13 IL2
5
Show member pathways
13.44 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
6
Show member pathways
13.42 CCL11 CCL17 CXCL8 IL13 IL2 IL3
7
Show member pathways
13.36 CCL11 CCL17 CXCL8 IL13 IL2 IL3
8
Show member pathways
12.98 CXCL8 IFNG IL2 TLR9 TNF
9
Show member pathways
12.94 IL2 IL3 IL4 NGF TNF
10 12.92 CXCL8 IFNG IL13 IL2 IL3 IL4
11
Show member pathways
12.88 CXCL8 ICAM1 IFNG IL13 IL2 IL4
12
Show member pathways
12.84 CD79A IFNG IL2 IL4 TLR9 TNF
13
Show member pathways
12.74 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
14
Show member pathways
12.72 IL2 IL3 NGF TLR9 TNF
15 12.68 CD79A IFNG IL2 IL3 IL4 TLR9
16
Show member pathways
12.67 CD79A IL13 IL3 IL4 IL5 TNF
17
Show member pathways
12.67 CXCL8 IFNG IL13 IL2 IL3 IL4
18
Show member pathways
12.61 ICAM1 IFNG IL2 IL3 IL4 TNF
19
Show member pathways
12.55 IFNG IL13 IL2 IL4 IL5 TNF
20
Show member pathways
12.48 IFNG IL2 IL4 IL5 TNF
21
Show member pathways
12.4 ICAM1 IFNG IL2 IL4 TNF
22
Show member pathways
12.34 CCL11 CCL17 CXCL8 IFNG IL13 IL4
23
Show member pathways
12.31 CCL11 CXCL8 IFNG IL4 TLR9 TNF
24
Show member pathways
12.28 IFNG IL2 TLR9 TNF
25
Show member pathways
12.24 CCL17 IL2 TLR9 TNF
26 12.21 CXCL8 IL13 NGF TNF
27 12.12 CXCL8 ICAM1 IFNG IL2 IL4 TNF
28
Show member pathways
12.08 IL13 IL2 IL5 TLR9
29 12.08 CCL11 CXCL8 ICAM1 IL13 IL4 TNF
30 12.04 CD79A IFNG IL2 IL3 IL4 IL5
31
Show member pathways
11.97 CCL11 CCL17 CXCL8
32 11.96 IL3 IL4 IL5 TNF
33
Show member pathways
11.95 IFNG IL2 IL4
34 11.93 CXCL8 ICAM1 IFNG TNF
35 11.92 CXCL8 IFNG IL3
36 11.89 CXCL8 ICAM1 TNF
37 11.89 IFNG IL13 IL2 IL4 IL5 TNF
38 11.87 CXCL8 IFNG TNF
39 11.87 CXCL8 ICAM1 TNF
40 11.84 IFNG IL2 TLR9 TNF
41 11.83 CXCL8 ICAM1 IFNG IL13 IL2 IL4
42
Show member pathways
11.8 CXCL8 ICAM1 IFNG IL2 TNF
43 11.76 CCL11 CCL17 IL4 IL5
44
Show member pathways
11.75 CXCL8 IFNG IL2 IL3 IL4 IL5
45 11.73 CCL11 CXCL8 IL13 IL4 IL5 TNF
46
Show member pathways
11.71 CCL11 CCL17 CXCL8 ICAM1 IFNG IL13
47
Show member pathways
11.67 IFNG IL2 TNF
48 11.67 CXCL8 ICAM1 IL13 IL4 TNF
49 11.66 CXCL8 ICAM1 IFNG TLR9 TNF
50 11.59 IFNG IL2 TNF

GO Terms for Keratoconjunctivitis

Cellular components related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.8 CCL11 CXCL8 IFNG IL2 IL3 IL5
2 extracellular region GO:0005576 9.8 AOC1 CCL11 CCL17 CXCL8 IFNG IL13
3 extracellular space GO:0005615 9.5 AOC1 CCL11 CCL17 CXCL8 ICAM1 IFNG
4 external side of plasma membrane GO:0009897 9.46 CD79A ICAM1 IL13 TNF

Biological processes related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.93 CCL17 IL2 IL3 NGF
2 MAPK cascade GO:0000165 9.89 IL2 IL3 IL5 TNF
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 CCL11 CCL17 ICAM1 TNF
4 inflammatory response GO:0006954 9.87 CCL11 CCL17 CXCL8 IL13 IL5 TLR9
5 response to ethanol GO:0045471 9.82 ICAM1 IL13 IL2
6 cytokine-mediated signaling pathway GO:0019221 9.81 CCL11 CXCL8 ICAM1 IL13 IL2 IL3
7 response to virus GO:0009615 9.8 CCL11 IFNG TNF
8 cellular response to interferon-gamma GO:0071346 9.79 CCL11 CCL17 ICAM1
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.77 ICAM1 IL3 IL5
10 cellular response to tumor necrosis factor GO:0071356 9.76 CCL11 CCL17 CXCL8 ICAM1
11 chemokine-mediated signaling pathway GO:0070098 9.74 CCL11 CCL17 CXCL8
12 neutrophil chemotaxis GO:0030593 9.73 CCL11 CCL17 CXCL8
13 cellular response to interleukin-1 GO:0071347 9.71 CCL11 CCL17 CXCL8 ICAM1
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.7 ICAM1 IFNG TNF
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 IFNG IL13 IL2 IL3
16 embryonic digestive tract development GO:0048566 9.65 CXCL8 TNF
17 negative regulation of endothelial cell apoptotic process GO:2000352 9.65 ICAM1 IL13 IL4
18 positive regulation of B cell proliferation GO:0030890 9.65 IL13 IL2 IL4 IL5 TLR9
19 immune response GO:0006955 9.65 CCL11 CCL17 CXCL8 IFNG IL13 IL2
20 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.64 IFNG TNF
21 regulation of regulatory T cell differentiation GO:0045589 9.64 IFNG IL2
22 response to molecule of bacterial origin GO:0002237 9.62 CXCL8 TLR9
23 positive regulation of immunoglobulin secretion GO:0051024 9.61 IL2 IL5
24 positive regulation of podosome assembly GO:0071803 9.61 IL5 TNF
25 positive regulation of isotype switching to IgG isotypes GO:0048304 9.58 IL2 IL4
26 positive regulation of immunoglobulin production GO:0002639 9.55 IL13 TLR9
27 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.54 ICAM1 TNF
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 IFNG TNF
29 negative regulation of complement-dependent cytotoxicity GO:1903660 9.49 IL13 IL4
30 positive regulation of vitamin D biosynthetic process GO:0060557 9.43 IFNG TNF
31 regulation of signaling receptor activity GO:0010469 9.36 CCL11 CCL17 CXCL8 IFNG IL13 IL2

Molecular functions related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.43 IL2 IL3 IL5
2 growth factor activity GO:0008083 9.35 IL2 IL3 IL4 IL5 NGF
3 chemokine activity GO:0008009 9.33 CCL11 CCL17 CXCL8
4 interleukin-1 receptor binding GO:0005149 9.32 IL3 TLR9
5 cytokine activity GO:0005125 9.32 CCL11 CCL17 CXCL8 IFNG IL13 IL2

Sources for Keratoconjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....